Do you want to read an article? Please log in or register.
ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients.
Diabetes - GeneralType 2 Diabetes
Related content
Diabetes - GeneralType 2 Diabetes
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Diabetes Care.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators
doi: 10.2337/dc18-1094.
Diabetes - GeneralType 2 Diabetes
Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
Diabetes Care.
Basu S, Raghavan S, Wexler DJ, Berkowitz SA
doi: 10.2337/dc17-2252.
COMMENTED
Type 2 Diabetes
Higher circulating omentin is associated with increased risk of primary cardiovascular events in individuals with diabetes
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetologia.
Niersmann C, Carstensen-Kirberg M, Maalmi H, Holleczek B, Roden M, Brenner H, Herder C, Schöttker B
doi: 10.1007/s00125-019-05017-2.
COMMENTED
Type 2 Diabetes
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M, CVD-REAL 2 Investigators and Study Group
doi: 10.1016/S2213-8587(20)30130-3.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study
BMJ
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S
doi: 10.1136/bmj.k2693.
COMMENTED
Diabetes - GeneralType 2 Diabetes
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
N Engl J Med.
Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, Gudbjörnsdottir S
doi: 10.1056/NEJMoa1800256.
Diabetes - General
Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials
Eur Heart J.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Ukena C, Mann JFE, Mancia G, Redon J, Schmieder RE, Sliwa K, Marx N, Weber MA, Williams B, Yusuf S
doi: 10.1093/eurheartj/ehy808.
Diabetes - GeneralType 2 Diabetes
Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
JAMA Cardiol.
Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E
doi: 10.1001/
COMMENTED
Diabetes - General
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk
Eur Heart J.
Böhm M, Schumacher H, Teo KK, Lonn EM, Mahfoud F, Mann JFE, Mancia G, Redon J, Schmieder RE, Marx N, Sliwa K, Weber MA, Williams B, Yusuf S
doi: 10.1093/eurheartj/ehz149.